Oncolytic Virus Cancer Therapy
Oncolytic viruses (OVs) is a cancer treatment using a native and reprogrammed virus that has a potential to targeting and killing cancerous cells and it represents a new class of cancer agents that promote tumor regression through preferential replication in tumor cells, induction of immunogenic cell death and stimulation of host antitumor immunity. These experimental cancer treatment that aims to employ viruses&amp;#39; inherent properties to aid in the battle against cancer. These non-human viruses multiply in cancer cells while mainly ignoring normal cells.
&nbsp;
<a style="color: black;" href="https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-epidemiology-forecast" target="_blank" rel="noopener noreferrer">Oncolytic Virus Cancer Therapy Epidemiology Segmentation in the 7MM</a>
<ul>
<li class="ql-align-justify">Total Incident cases of Selected Cancer Types</li>
<li class="ql-align-justify">Target Patient Pool of Oncolytic Virus Cancer Therapy by Cancer Types</li>
<li class="ql-align-justify">Total Treated Cases by Line of Therapies</li>
</ul>
&nbsp;
Oncolytic Virus Cancer Therapy Epidemiological Insights Observed in the 7MM (2022)
The total number of incident cases of Oncolytic Virus Cancer Therapy observed in the 7MM was observed to be 640 K in the year 2022
&nbsp;
Oncolytic Virus Cancer Therapy Market Strengths
Compared with other tumor immunotherapies, OVs have many advantages, such as high killing efficiency, precise targeting, fewer side effects or drug resistance, and low cost.
&nbsp;
Oncolytic Virus Cancer Therapy Market Opportunities
To work as a vaccine for cancer as certain OVs like Adeno OVs have shown capacity of antitumor memory.
&nbsp;
<a style="color: black;" href="https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-pipeline-insight-2021" target="_blank" rel="noopener noreferrer">Oncolytic Virus Cancer Therapy Emerging Drugs and Key companies</a>
<ul>
<li class="ql-align-justify">ONCOS-102: Targovax</li>
<li class="ql-align-justify">RP1 (Vusolimogene Oderparepvec): Replimune</li>
<li class="ql-align-justify">GL-ONC1: Genelux Corporation</li>
<li class="ql-align-justify">CAN-2409: Candel Therapeutics</li>
<li class="ql-align-justify">DNX-2401 (Tasadenoturev): DNAtrix</li>
<li class="ql-align-justify">PEXA-VEC (Pexastimogene Devacirepvec; JX-594): SillaJen</li>
<li class="ql-align-justify">G207: Treovir</li>
<li class="ql-align-justify">LOAd703: Lokon Pharma AB</li>
<li class="ql-align-justify">Lerapolturev (Formerly Known as PVSRIPO): Istari Oncology</li>
<li class="ql-align-justify">CG0070: CG Oncology</li>
</ul>

Oncolytic Virus Infographic

Oncolytic Virus Pipeline

Oncolytic Virus Infographic gives a brief about the treatment therapies, companies, overview and Oncolytic Virus report features.